AnaptysBio gains as GSK granted FDA label expansion for Jemperli

RegulatoryapprovedJemperliPositive

AI Analysis

Summary

AnaptysBio shares gained after GSK received an FDA label expansion for Jemperli (dostarlimab), on which AnaptysBio is entitled to royalties. Details of the expanded indication were not provided.

Outcome Details

FDA granted a label expansion for GSK's Jemperli; specific indication not stated in the available text.

Importance:6/10

Sentiment:

0.60

FDAlabel expansionroyaltyoncologyPD-1

Related Companies

$ANAB $GSK

Read the original article

Published by Seeking Alpha Healthcare on October 19, 2026 5:25 PM

Read Original